- Conditions
- Systemic Lupus Erythematosus of Childhood (Disorder)
- Interventions
- TEACH
- Behavioral
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 12 Years to 22 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • New Orleans, Louisiana • Grand Rapids, Michigan + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Fibromyalgia
- Interventions
- No Intervention
- Other
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Systemic Lupus Erythematosus, Quality of Life
- Interventions
- Not listed
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Pillsy
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Atorvastatin, Placebo atorvastatin
- Drug
- Lead sponsor
- Laura Schanberg
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
- Interventions
- Descartes-08
- Drug
- Lead sponsor
- Cartesian Therapeutics
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • St Louis, Missouri
- Conditions
- Brain Tumor
- Interventions
- Bright Light Exposure, Dim Light Exposure, Cognitive Assessment
- Behavioral · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
- Conditions
- Osteoporosis, Juvenile Rheumatoid Arthritis, Dermatomyositis, Polyarthritis, Systemic Lupus Erythematosis, Vasculitis, Glucocorticoid-induced Osteoporosis
- Interventions
- denosumab
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 4 Years to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)
- Interventions
- Use of decision support tool, Use of UpToDate
- Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus of Childhood, Joint Hypermobility, Juvenile Dermatomyositis
- Interventions
- FIT Teens
- Behavioral
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 19 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab 10 mg/kg, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more
- Conditions
- Lupus, Dermatomyositis, Juvenile, Dermatomyositis, Lupus Erythematosus, Lupus Erythematosus, Systemic, Lupus or SLE
- Interventions
- TEAM-LEADS
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 13 Years to 22 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Placebo
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 18 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Vitamin D3 6000 IU, Vitamin D3 400 IU
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 5 Years to 20 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- TEACH
- Behavioral
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 12 Years to 22 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan